FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136368617> ?p ?o ?g. }

• W3136368617 endingPage "S640" @default.
• W3136368617 startingPage "S639" @default.
• W3136368617 abstract "Pembrolizumab monotherapy is the preferred treatment option for patients with stage IV non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor expression ≥ 50% and no actionable driver mutations. There is little real word data on immune-related adverse events (irAEs) with first-line pembrolizumab. In this study, we aim to better understand irAE incidence, risk factors, and impact on clinical outcome in treatment naïve patients receiving first-line pembrolizumab therapy. We conducted a multicenter, retrospective study of patients with treatment-naïve NSCLC and a PD-L1 expression of ≥50% treated with first line pembrolizumab monotherapy between June 2016 and January 2020. irAEs were determined by treating physician diagnosis and lack of alternative etiologies. Risk factors for irAE occurrence were determined using a logistic regression model. Overall survival (OS) was measured from the date of therapy initiation to death or the last point of follow-up. Survival was estimated by the Kaplan-Meier method. Cox proportional hazards were used to determine the association between irAE and OS while treating irAE as a time-dependent variable. P < 0.05 was considered significant. In our cohort of 153 patients, the median age was 66 years old (range 41-90); 37% of patients were female, 76.4% of patients had adenocarcinoma, and 21.5% had squamous cell carcinoma. Median follow-up time was 12 months. irAEs occurred in 65 patients (42.4%) with 23 (15.1%) developing irAE CTCAE grade ≥ 3. The most common high grade irAEs were pneumonitis (n=9), colitis (n=6), and hepatitis (n=2). Higher risk for irAE was associated with current tobacco use or cessation of tobacco use <6 months prior to treatment start (odds ratio [OR] 2.27, 95% confidence interval [CI] 1.14-4.52, P=0.02), prior or concurrent radiation therapy (OR 2.03, 95 %CI 1.06-3.90, P=0.03), neutrophil-lymphocyte ratio (NLR) >5 prior to starting therapy (OR 2.33, 95% CI 1.19-4.56, P=0.01), and longer course of pembrolizumab treatment (OR 1.039 per cycle, 95% CI 1.009-1.070, p=0.011). There was no difference in OS between patients who experienced low grade irAEs (<3) and those who did not develop irAEs (HR=0.391, 95% CI 0.124-1.231, p=0.1325) while those who developed high grade irAEs (≥ 3) had worse OS (HR 2.419, 95% CI, 1.117-5.243, p=0.021). Of patients who developed any grade irAEs, those who discontinued pembrolizumab therapy after irAE were found to have worse OS than those who continued therapy (HR 3.178, 95% CI 1.14-8.83, p=0.03). Risk factors for the development of irAEs during first-line pembrolizumab included current or recent smoking status, NLR >5 prior to treatment start, prior or concurrent radiation therapy, and longer exposure to therapy. Higher grade irAEs and those events leading to discontinuation were associated with worse OS, and no OS benefit was observed in patients with lower grade adverse events. Our study identifies patients at high risk for irAEs who may benefit from closer monitoring during therapy. The lack of survival benefit from irAE in NSCLC patients with high PD-L1 expression has not previously been reported and warrants further investigation." @default.
• W3136368617 created "2021-03-29" @default.
• W3136368617 creator A5004712121 @default.
• W3136368617 creator A5006468163 @default.
• W3136368617 creator A5007827037 @default.
• W3136368617 creator A5017537551 @default.
• W3136368617 creator A5021394498 @default.
• W3136368617 creator A5025836672 @default.
• W3136368617 creator A5028299369 @default.
• W3136368617 creator A5030996697 @default.
• W3136368617 creator A5053769864 @default.
• W3136368617 creator A5059652753 @default.
• W3136368617 creator A5059895822 @default.
• W3136368617 creator A5066306817 @default.
• W3136368617 creator A5070734531 @default.
• W3136368617 creator A5075792907 @default.
• W3136368617 creator A5079716545 @default.
• W3136368617 creator A5080912779 @default.
• W3136368617 creator A5087704838 @default.
• W3136368617 creator A5090253314 @default.
• W3136368617 creator A5091280788 @default.
• W3136368617 creator A5043538122 @default.
• W3136368617 date "2021-03-01" @default.
• W3136368617 modified "2023-10-12" @default.
• W3136368617 title "P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome" @default.
• W3136368617 doi "https://doi.org/10.1016/j.jtho.2021.01.1168" @default.
• W3136368617 hasPublicationYear "2021" @default.
• W3136368617 type Work @default.
• W3136368617 sameAs 3136368617 @default.
• W3136368617 citedByCount "0" @default.
• W3136368617 crossrefType "journal-article" @default.
• W3136368617 hasAuthorship W3136368617A5004712121 @default.
• W3136368617 hasAuthorship W3136368617A5006468163 @default.
• W3136368617 hasAuthorship W3136368617A5007827037 @default.
• W3136368617 hasAuthorship W3136368617A5017537551 @default.
• W3136368617 hasAuthorship W3136368617A5021394498 @default.
• W3136368617 hasAuthorship W3136368617A5025836672 @default.
• W3136368617 hasAuthorship W3136368617A5028299369 @default.
• W3136368617 hasAuthorship W3136368617A5030996697 @default.
• W3136368617 hasAuthorship W3136368617A5043538122 @default.
• W3136368617 hasAuthorship W3136368617A5053769864 @default.
• W3136368617 hasAuthorship W3136368617A5059652753 @default.
• W3136368617 hasAuthorship W3136368617A5059895822 @default.
• W3136368617 hasAuthorship W3136368617A5066306817 @default.
• W3136368617 hasAuthorship W3136368617A5070734531 @default.
• W3136368617 hasAuthorship W3136368617A5075792907 @default.
• W3136368617 hasAuthorship W3136368617A5079716545 @default.
• W3136368617 hasAuthorship W3136368617A5080912779 @default.
• W3136368617 hasAuthorship W3136368617A5087704838 @default.
• W3136368617 hasAuthorship W3136368617A5090253314 @default.
• W3136368617 hasAuthorship W3136368617A5091280788 @default.
• W3136368617 hasBestOaLocation W31363686171 @default.
• W3136368617 hasConcept C120665830 @default.
• W3136368617 hasConcept C121332964 @default.
• W3136368617 hasConcept C121608353 @default.
• W3136368617 hasConcept C126322002 @default.
• W3136368617 hasConcept C143998085 @default.
• W3136368617 hasConcept C167135981 @default.
• W3136368617 hasConcept C197934379 @default.
• W3136368617 hasConcept C2776256026 @default.
• W3136368617 hasConcept C2777701055 @default.
• W3136368617 hasConcept C2777714996 @default.
• W3136368617 hasConcept C2779524853 @default.
• W3136368617 hasConcept C2780057760 @default.
• W3136368617 hasConcept C2781182431 @default.
• W3136368617 hasConcept C50382708 @default.
• W3136368617 hasConcept C61511704 @default.
• W3136368617 hasConcept C71924100 @default.
• W3136368617 hasConcept C72563966 @default.
• W3136368617 hasConceptScore W3136368617C120665830 @default.
• W3136368617 hasConceptScore W3136368617C121332964 @default.
• W3136368617 hasConceptScore W3136368617C121608353 @default.
• W3136368617 hasConceptScore W3136368617C126322002 @default.
• W3136368617 hasConceptScore W3136368617C143998085 @default.
• W3136368617 hasConceptScore W3136368617C167135981 @default.
• W3136368617 hasConceptScore W3136368617C197934379 @default.
• W3136368617 hasConceptScore W3136368617C2776256026 @default.
• W3136368617 hasConceptScore W3136368617C2777701055 @default.
• W3136368617 hasConceptScore W3136368617C2777714996 @default.
• W3136368617 hasConceptScore W3136368617C2779524853 @default.
• W3136368617 hasConceptScore W3136368617C2780057760 @default.
• W3136368617 hasConceptScore W3136368617C2781182431 @default.
• W3136368617 hasConceptScore W3136368617C50382708 @default.
• W3136368617 hasConceptScore W3136368617C61511704 @default.
• W3136368617 hasConceptScore W3136368617C71924100 @default.
• W3136368617 hasConceptScore W3136368617C72563966 @default.
• W3136368617 hasIssue "3" @default.
• W3136368617 hasLocation W31363686171 @default.
• W3136368617 hasOpenAccess W3136368617 @default.
• W3136368617 hasPrimaryLocation W31363686171 @default.
• W3136368617 hasRelatedWork W2040381674 @default.
• W3136368617 hasRelatedWork W2131562451 @default.
• W3136368617 hasRelatedWork W2351757746 @default.
• W3136368617 hasRelatedWork W2362760700 @default.
• W3136368617 hasRelatedWork W2898071776 @default.
• W3136368617 hasRelatedWork W2990069822 @default.
• W3136368617 hasRelatedWork W3041652591 @default.
• W3136368617 hasRelatedWork W3175277114 @default.

• next